solid tumor
Conditions
Interventions
None listed
Sponsors
National Cancer Center Hospital East
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Gene panel performance confirmation part: 1) Patients enrolled in prospective observational study to clarify genetic abnormalities in lung cancer and their clinicopathologic, molecular biological characteristics, and resistance mechanism of cancer therapeutic agents. 2) Secondary use of specimens by using a written consent document explaining prospective observational study to clarify genetic abnormalities in lung cancer and their clinicopathologic, molecular biological characteristics, and resistance mechanism of cancer therapeutic agents, And there are enough samples to carry out the genetic analysis of this study. 3) Patients with ROS1 rearrangement positive lung cancer or ROS1 rearrangement negative lung cancer Efficacy / resistance analysis part: 1) Cases registered in basket study of brigatinib in patients with advanced solid tumors with ROS1 rearrangement. 2) Among the subjects who obtained consent to provide samples for the accompanying study using the informed consent document of basket study of brigatinib in patients with advanced solid tumors with ROS1 rearrangement, There are enough samples to perform the analysis.
Exclusion criteria
Exclusion criteria: non
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To evaluate the relationship between the gene abnormalities before, during, and after treatment with brigatinib and the therapeutic effect, and to explore the molecular mechanism related to the efficacy and resistance of brigatinib in ROS1 fusion gene-positive solid tumors. | — |
Countries
Japan
Contacts
Public ContactTakaya Ikeda
National Cancer Center Hospital East Department of Thoracic Oncology
Outcome results
None listed